Seven Biopharma Trends to Watch in 2026: Clinical Trials Insights
Decision brief
Answer first · skim in under a minute
As we approach 2026, several biopharma trends are set to reshape clinical trials. This article outlines critical insights for investors and business development teams.
Seven Biopharma Trends to Watch in 2026: Clinical Trials Insights should be grounded in FDA primary documents, not buzzwords. The highest-signal 2026 trial themes are enrollment representativeness, adaptive design use, digital health technologies for remote data, AI transparency in submissions, manufacturing-facility predictability via PreCheck, China out-licensing as a protocol-sourcing channel, and biomarker-enriched oncology development.
Contents10 sections
Key Takeaways
- FDA finalized updated participation guidance in December 2025 addressing eligibility criteria, enrollment practices, and adaptive design options.
- FDA’s DHT guidance sets expectations for fit-for-purpose remote data capture tools in clinical investigations.
- FDA PreCheck applications opened February 1, 2026 for new U.S. manufacturing facilities — a CMC trend that affects study-supply readiness.
- Reuters-reported China out-licensing reached $137.7 billion in 2025 deal value, shaping where global sponsors source Phase 2/3 assets.
What enrollment trend will shape protocols in 2026?
FDA’s Enhancing Participation in Clinical Trials guidance (December 2025) urges sponsors to reduce unnecessary eligibility exclusions and to consider adaptive designs that can expand populations when interim safety supports broader enrollment. It also discusses remote communication and digital tools to reduce geographic barriers.
Operational implication: protocols that still copy legacy exclusions without pharmacokinetic or safety justification face harder FDA questions and slower enrollment. CI teams should track whether competitors redesign inclusion criteria mid-program under pre-specified adaptive rules.
Primary: FDA clinical guidances index (lists December 2025 participation guidance) and FDA participation guidance PDF (media/190162).
How will digital health technologies change trial operations?
FDA’s final guidance on Digital Health Technologies for Remote Data Acquisition asks sponsors to justify that a DHT is fit-for-purpose, with verification, validation, and usability evidence matched to the endpoint and population. That raises the bar for wearables and apps used as primary or key secondary endpoints.
Trend to watch: protocols that treat DHT outputs as exploratory versus those seeking label-claim endpoints with full DHT validation packages.
Primary: FDA DHT remote data acquisition guidance PDF.
Where do AI, adaptive enrichment, and manufacturing intersect trials?
FDA has published research and draft thinking on AI-enabled device software lifecycle management and on evaluating AI for adaptive enrichment designs. Sponsors using AI for site selection, enrichment, or endpoint adjudication should expect questions about training data representativeness and bias controls.
Separately, FDA PreCheck (applications from February 1, 2026) aims to improve predictability for new U.S. drug manufacturing facilities. Trial supply failures are a silent enrollment killer; facility readiness is therefore a clinical operations trend, even though PreCheck is not a clinical review program.
See FDA PreCheck launch announcement.
How China licensing and biomarker oncology reshape trial portfolios
Reuters reported greater China-region out-licensing deal value of $137.7 billion in 2025, with 2026 average deal size and upfront fees rising further per Pharmcube figures cited in that reporting. Global sponsors increasingly in-license China-origin assets into multinational Phase 2/3 programs, changing where protocols originate and how bridging strategies are written.
In oncology, biomarker-enriched designs (for example, DKK1-high CRC subsets in recent Phase 2 work) remain a template: positive subgroup signals force sponsors to choose broad versus enriched Phase 3 strategies under FDA adaptive-design principles.
Market context: Reuters: China biotech licensing boom (Feb 13, 2026).
Seven trends in one screening list
- 1) Broader eligibility and adaptive expansion (FDA Dec 2025 guidance)
- 2) DHT fit-for-purpose validation for remote endpoints
- 3) AI transparency and bias controls in enrichment tools
- 4) PreCheck-driven U.S. manufacturing predictability (from Feb 1, 2026)
- 5) China-origin asset in-licensing into global trials ($137.7B 2025 deal value reported)
- 6) Biomarker-enriched oncology Phase 3 choices
- 7) QIDP/antibacterial and specialty registration pathways feeding ID trial volume
What remains unproven
These trends do not guarantee faster Phase 3 success rates in 2026. Guidance documents are recommendations; deal-value tallies are market data, not efficacy. Do not invent enrollment percentage improvements or AI accuracy claims without study-level evidence.
Related NovaPharma coverage
Frequently Asked Questions
What FDA documents define 2026 clinical-trial participation expectations?
FDA’s December 2025 guidance on Enhancing Participation in Clinical Trials covers eligibility criteria, enrollment practices, and trial designs, including adaptive approaches and remote communication tools.
How does FDA treat digital health technologies in trials?
FDA’s final DHT guidance recommends fit-for-purpose selection, verification/validation, and usability evaluation when DHTs are used for remote data acquisition in clinical investigations.
Is FDA PreCheck a clinical-trial trend?
No. PreCheck is a 2026 manufacturing-facility pilot. It is adjacent CMC infrastructure, not a clinical endpoint or diversity-enrollment program.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
